B.C. pharmaceutical company’s stocks double in value after successful lupus drug trial

More than 40 per cent of patients using voclosporin saw improvements in kidney function

Saanich-based pharmaceutical company, Aurinia Pharmaceuticals, saw share values soar on Thursday after success with clinical trials for a new lupus drug.

On Dec. 4, the company announced that results from the AURORA Phase 3 drug trials for voclosporin had been successful in treating kidney inflammation in patients with lupus nephritis – an autoimmune disease.

Aurinia’s chief medical officer Neil Solomons explained that patients with lupus can experience “irreversible kidney damage” that can lead to kidney failure and death.

READ ALSO: Saanich biotech company secures $52M US for global drug study

The study included 357 patients from around the world with lupus and the results showed that participants using voclosporin experienced a “renal response rate” of 40.8 per cent while just 22.5 per cent of participants in the control group – those who didn’t receive the drug – saw improvements.

Data also indicated that the group taking voclosporin saw no more adverse events than the group receiving standard lupus treatment, noted Brad Rovin, chief of the nephrology division at the Ohio State University Wexner Medical Centre.

Following the announcement of the drug’s successful Phase 3 trial, the company’s share price exploded on Thursday, rising from Wednesday’s close of $11.13 per share to touch a 52-week high of $23.04 before closing at $19.75. Its shares have risen from a 52-week low of $4.70 to close Friday at $20.48 – a gain of 336 per cent, driving the company’s market cap to $1.93 billion.

READ ALSO: Mental health call temporarily shuts down Trans Canada Highway in View Royal

Lupus has historically been difficult to treat and new treatment options were needed, said Stevan Gibson, president and CEO of the Lupus Foundation of America. Voclosporin is the first effective therapeutic treatment option and the successful trial marks a step forward in treating the potentially deadly disease, he noted.

Chief executive Peter Greenleaf noted that staff were “thrilled with the outcomes” of the trial and that the drug’s success is significant for people living with lupus – close to 3 million people worldwide. The company is planning to put the drug on the market as early as 2021, but first it must pass though the U.S. Food and Drug Administration (FDA) process. The drug was given a fast track by the FDA in 2016 and the company plans to submit to the FDA in early 2020.

With files from Paul Bucci.


@devonscarlett
Like us on Facebook and follow us on Twitter.

devon.bidal@saanichnews.com

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Tax hikes possible in Township as budget talks begin

Just “keeping the lights on” could cost 4.12 per cent in tax increases

How to beat Blue Monday, the most depressing day of the year

Multiple factors can play a role in seasonal depression, says Fraser Health psychiatrist

Langleyites get their say about proposed community gardens at Rotary Centennial Park

38 plots and an additional eight garden spaces have been put forth for Langley City park

VIDEO: Vancouver Giants burned by Kamloops Blazers

Home ice loss sees Kamloops extend winning streak to eight

Update: Burned-up vehicle in Langley residential neighbourhood linked to Burnaby murder

Integrated Homicide Investigation Team (IHIT) issues appeal for witnesses

VIDEO: Soldiers trade rifles for snow shovels to help dig out St. John’s

A state of emergency is set to extend into a fifth day

Warm ‘blob’ could be behind mass starvation of North Pacific seabirds: study

Unprecedented death toll raises red flag for North American marine ecosystems

Convicted Fraser Valley con man facing 39 charges in Vancouver area

Donald Quinnell got four years prison in 2015, again facing fraud, theft, stolen credit card charges

Police seize nearly 50 kilos of drugs in Surrey

Police say this has taken perhaps millions of deadly doses of fentanyl and other drugs off the streets

Young child seriously injured in suspected drunk driving crash in Delta

“This needs to stop,” says Insp. Ciaran Feenan, head of the Delta Police Department’s patrol section

Elderly man in serious condition after being hit by bus in Burnaby

RCMP believe man, 82, was not at a crosswalk at the time

ICBC to bring in ranking system for collision, glass repair shops

Change comes after the much-maligned auto insurer has faced criticism for sky-high premiums

Most Read